Tonix Pharmaceuticals Holding Corp. presented Phase 1 data for its Lyme‑disease antibody candidate TNX‑4800 at the World Vaccine Congress in Washington, D.C., on March 30, 2026. The announcement of the presentation was made the following day, March 31, 2026.
The single‑dose study enrolled 44 subjects, 41 of whom completed the protocol. Doses ranged from 0.5 to 10 mg/kg administered subcutaneously. No significant safety signals emerged; most adverse events were mild or moderate, underscoring the antibody’s tolerability profile.
Pharmacokinetic analysis showed rapid absorption and protective serum concentrations maintained for at least four months. The mean half‑life was 62‑69 days, and serum levels remained quantifiable in most subjects for up to 12 months, supporting a single‑dose, seasonal protection strategy.
The data advance TNX‑4800 toward a potential first‑in‑class, single‑dose prophylactic for Lyme disease—a condition for which no FDA‑approved vaccine or prophylactic exists. The company plans to initiate an adaptive Phase 2 field study in the first half of 2027, pending FDA clearance. The 87 million U.S. residents at high risk for Lyme disease represent a sizable market opportunity for a product that could fill a critical unmet need.
CEO Seth Lederman said, "TNX‑4800 is expected to provide a preventative option to the 87 million people in the United States who are at high risk of contracting the disease because they live, work, or vacation in a tick‑endemic area." Dr. Mark S. Klempner, professor of medicine at UMass Chan Medical School and inventor of TNX‑4800, added, "Preventing Lyme disease is an urgent public health priority, and more than 30 years of clinical experience confirms that monoclonal antibodies can be delivered safely and are effective in preventing infections."
The announcement comes amid a competitive landscape that includes Pfizer‑Valneva’s VLA15 vaccine candidate and a long development timeline for TNX‑4800. While the company’s financials show large operating losses and negative cash flow, revenue and gross margin are improving, indicating that the company is investing heavily in its pipeline while managing costs. The Phase 1 results provide a strong foundation for the next phase of clinical development and could broaden the commercial prospects of Tonix’s infectious‑disease portfolio.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.